N@N

Andrew Fein Upgraded (ACAD) to Strong Buy and Increased Target to $36 on, Feb 9th, 2022

Andrew Fein of HC Wainwright & Co., Upgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Strong Buy and Increased Target from $18 to $36 on, Feb 9th, 2022.

Andrew has made no other calls on ACAD in the last 4 months.

There are 10 other peers that have a rating on ACAD. Out of the 10 peers that are also analyzing ACAD, 7 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Increased Target to $30 on, Wednesday, December 22nd, 2021
• Tazeen Ahmad of "B of A Securities" Maintained at Hold with Increased Target to $32 on, Tuesday, December 21st, 2021
• Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Held Target at $28 on, Tuesday, December 21st, 2021
• Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $23 on, Thursday, December 9th, 2021
• Salveen Richter of "Goldman Sachs" Maintained at Hold with Increased Target to $28 on, Wednesday, December 8th, 2021
• Vamil Divan of "Mizuho" Maintained at Hold with Increased Target to $26 on, Tuesday, December 7th, 2021
• Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $24 on, Tuesday, December 7th, 2021

These are the ratings of the 3 analyists that currently disagree with Andrew

---

• Neena Bitritto-Garg of "Citigroup" Upgraded from Hold to Strong Buy and Held Target at $30 on, Wednesday, January 5th, 2022
• Gregory Renza of "RBC Capital" Maintained at Buy with Increased Target to $34 on, Tuesday, December 21st, 2021
• Jason Butler of "JMP Securities" Maintained at Buy with Increased Target to $42 on, Tuesday, December 21st, 2021

Contributing Sources

---